AACR POSTER – Selectivity
Unbiased Selectivity Profiling with CETSA® and Mass Spectrometry
Unbiased Selectivity Profiling: Revealing True Compound Specificity and Off-Target Interactions
In drug discovery, ensuring selectivity and minimizing off-target effects are crucial for improving the safety and efficacy of therapeutic compounds. Pelago Bioscience’s Selectivity Profiling Service, powered by CETSA (Cellular Thermal Shift Assay) coupled with mass spectrometry, offers a comprehensive, unbiased approach to assess compound interactions across over 5,000 proteins. This innovative service enables precise identification of both on-target and off-target proteins, including those often missed by conventional screening panels.
Our service provides a clear understanding of compound selectivity and potency, helping researchers prioritize lead compounds early in the discovery process and avoid potential liabilities. By profiling well-known probes and marketed drugs, such as Abemaciclib and Palbociclib, we demonstrate how unbiased profiling reveals key off-target interactions and highlights the need for early identification of promiscuous compounds. This approach ensures that selectivity profiling is comprehensive, reproducible, and scalable, supporting informed decision-making for the advancement of drug candidates.
Explore how our CETSA-based Selectivity Profiling can help refine your drug discovery efforts and optimize lead selection.
You might also be interested in
CETSA as a tool for assessing selectivity of warheads and PROTACS and for detecting binders that remain intact
CETSA® (Cellular Thermal Shift Assay) is an effective method for studying interactions between …
How CETSA® Enhances Translational Studies – A Sitryx Case Study
Bridging the Gap Between In Vitro and In Vivo Drug Discovery Translating early-stage drug…
Is Your Hit on Target?
Validate Early with CETSA® Accelerate hit confirmation and lead optimization with CETSA® …